title: The coagulo-lytic system and endothelial function in cyclosporine-treated kidney allograft recipients.
abstract: Since thromboembolic complications in transplanted patients are generally attributed to combined abnormalities in platelets and coagulo-lytic system, some hemostatic parameters tPA (tissue plasmogin activator):Ag and activity, its inhibitor-PAIAg and activity, tPA/PAI, thrombin-antithrombin (TAT) and plasmin-antiplasmin complexes (PAP), urokinase-uPA, euglobulin clot lysis time-ECLT, fibrinogen, plasminogen, protein C activity, D-dimer, prothrombin fragments1+2 (F1+2), fibrin monomers, fibronectin, lipoprotein-a, and von Willebrand factor(vWF), were evaluated using commercially available kits. The studies were performed on kidney transplant recipients treated with CsA, azathioprine and prednisone (n=21), and healthy volunteers (n=21). ECLT was significantly prolonged in kidney transplant recipients together with a rise in F1+2,lipoprotein-a, fibrinogen, fibronectin, and vWF when compared with controls. The TPA level was lower, whereas the PAI level was higher in kidney transplant recipients when compared with controls. In conclusion, CsA-treated kidney transplant recipients show evidence of pronounced impairment in fibrinolysis and endothelial damage in comparison with healthy volunteers.
authors.affiliation: Nephrology Department, Medical School, Zurawia, Poland.
authors.forename: J
authors.initials: J
authors.lastname: Malyszko
authors.forename: J S
authors.initials: JS
authors.lastname: Malyszko
authors.forename: K
authors.initials: K
authors.lastname: Pawlak
authors.forename: M
authors.initials: M
authors.lastname: Mysliwiec
mesh_terms: D000328:Adult; D001777:Blood Coagulation / Q000187:drug effects*; D001779:Blood Coagulation Factors / Q000032:analysis; D016572:Cyclosporine / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000502:physiology; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D005342:Fibrinolysis / Q000187:drug effects*; D005353:Fibronectins / Q000032:analysis; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis; D011239:Prednisolone / Q000627:therapeutic use; D013923:Thromboembolism / Q000097:blood / Q000139:chemically induced; D010959:Tissue Plasminogen Activator / Q000032:analysis; D014568:Urokinase-Type Plasminogen Activator / Q000032:analysis; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D001779:Blood Coagulation Factors; D005338:Fibrin Fibrinogen Degradation Products; D005353:Fibronectins; D007166:Immunosuppressive Agents; D017395:Plasminogen Activator Inhibitor 1; D015215:Zidovudine; D016572:Cyclosporine; D005340:Fibrinogen; D011239:Prednisolone; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator